TNF superfamily gene polymorphism as prognostic factor in early breast cancer |
| |
Authors: | Jin Hyang Jung Yee Soo Chae Joon Ho Moon Byung Woog Kang Jong Gwang Kim Sang Kyun Sohn Ji Young Park Myung Hoon Lee Ho Yong Park |
| |
Institution: | 1. Department of Surgery, Kyungpook National University Hospital, Kyungpook National University School of Medicine, 50 Samduk 2-Ga, Jung-Gu, Daegu, 700-721, Korea 2. Department of Oncology/Hematology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, 50 Samduk 2-Ga, Jung-Gu, Daegu, 700-721, Korea 3. Department of Pathology, Kyungpook National University Hospital, Kyungpook National University School of Medicine, Daegu, Korea 4. Technology Center for Diagnosis and Prediction, Kyungpook National University School of Medicine, Daegu, Korea
|
| |
Abstract: | Purpose Since apoptosis may play a role in the prognosis of breast cancer, the present study analyzed the polymorphisms of apoptosis-related genes and their impact on the survival of 240 patients with early invasive ductal breast cancer. Methods The genomic DNA was extracted from paraffin-embedded tumor-free tissue or blood, and 12 single nucleotide polymorphisms (SNPs) of 11 apoptosis-related genes in the apoptosis pathway determined using a Sequenom MassARRAY system. Results During the median follow-up of 53.4 (range 2.9–205.9) months, 37 relapses and 22 deaths occurred. Among the target polymorphisms, the tumor necrosis factor superfamily member 10 gene polymorphism (TNFSF10 rs1131532) in a recessive model of the T allele and prostaglandin-endoperoxide synthase 2 gene polymorphism (PTGS2 rs5275) in a dominant model of the C allele were associated with survival in a log-rank test. The TT genotype of TNFSF10 (rs1131532) was also significantly correlated with a lower disease-free, distant disease-free, and overall survival in a multivariate analysis (HR = 3.304, 4.757, and 6.459; P = 0.002, 0.001, and 0.009, respectively), while PTGS2 rs5275 was only associated with a higher distant disease-free survival (HR = 0.302; P = 0.041). No clinicopathologic difference was observed according to the genotypes of these two polymorphisms. Conclusion The TNFSF10 (rs1131532) polymorphism was identified as a possible prognostic factor of survival in patients with operated invasive breast cancer. |
| |
Keywords: | |
本文献已被 SpringerLink 等数据库收录! |
|